Treating Lower Respiratory Infection with Imported and Domestic Cefoperazone/Sulbactam Sodium:Cost-effectiveness Analyses / 中国药房
China Pharmacy
; (12)2001.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-527541
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE:
To evaluate the cost-effectiveness of imported and domestic cefoperazone/sulbactam sodium in treating lower respiratory infection.METHODS:
60patients with lower respiratory infections were ascribed to receive im-ported or domestic cefoperazone/sulbactam sodium(2∶1)respectively,the curative effects of the drugs were monitored and evaluated by cost-effectiveness analysis.RESULTS:
The costs of the two groups were3164.00yuan and828.80yuan,re-spectively(P0.05),respectively;The cost-effectiveness ratios were37.98and10.36,respectively;And the incremental cost-effectiveness ratio of the imported group vs.the domestic group was707.64.CONCLUSION:
Domestic cefoperazone/sulbactam sodium is a more economical choice.
Texto completo:
Disponível
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
Problema de saúde:
Objetivo 4: Financiamento para a saúde
Base de dados:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Avaliação econômica em saúde
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2001
Tipo de documento:
Artigo
